Brainstorm Cell Therapeutics Inc. stock is up 46% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 26.32% of the previous 19 November’s closed higher than October. In the last 5 Unusual Options Trades, there were 5 PUTs.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|02 Oct 15:03||17 Nov, 2023||1.00||6327|
|02 Oct 19:24||17 Nov, 2023||1.00||6327|
|03 Oct 13:31||17 Nov, 2023||1.00||5728|
|03 Oct 13:32||17 Nov, 2023||1.00||5728|
|23 Oct 17:55||16 Feb, 2024||2.00||1897|
Brainstorm Cell Therapeutics Inc. engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. It is developing NurOwn, which has completed Phase III clinical trial for the. treatment of amyotrophic lateral sclerosis; and Phase II clinical trial. for. progressive multiple sclerosis and alzheimer's disease. The company was formerly known as Golden Hand Resources Inc.